Market capitalization | $2.12b |
Enterprise Value | $2.34b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.63 |
P/S ratio (TTM) P/S ratio | 3.29 |
P/B ratio (TTM) P/B ratio | 2.33 |
Revenue growth (TTM) Revenue growth | 12.06% |
Revenue (TTM) Revenue | $644.12m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
15 Analysts have issued a NeoGenomics, Inc. forecast:
15 Analysts have issued a NeoGenomics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 644 644 |
12%
12%
|
|
Gross Profit | 261 261 |
20%
20%
|
|
EBITDA | -13 -13 |
46%
46%
|
EBIT (Operating Income) EBIT | -86 -86 |
17%
17%
|
Net Profit | -78 -78 |
19%
19%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Head office | United States |
CEO | Chris Smith |
Employees | 2,100 |
Founded | 1998 |
Website | www.neogenomics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.